CNCE
Concert Pharmaceuticals, Inc.
CNCE
CNCE
Delisted
CNCE was delisted on the 3rd of March, 2023.
93 hedge funds and large institutions have $222M invested in Concert Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 42 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
93
Holders Change
-18
Holders Change %
-16.22%
% of All Funds
2.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
27
Reduced
42
Closed
27
Calls
$176K
Puts
$432K
Net Calls
-$256K
Net Calls Change
-$4K
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$22.8M |
| 2 |
RI
RTW Investments
New York
|
+$9.9M |
| 3 |
First Manhattan
New York
|
+$6.08M |
| 4 |
Millennium Management
New York
|
+$5.92M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.33M |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$5.54M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$4.42M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.43M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.03M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$2.62M |
